Journal article
Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies
Expert opinion on biological therapy, Vol.17(3), pp.265-283
03/04/2017
DOI: 10.1080/14712598.2017.1287169
PMID: 28117616
Abstract
Introduction: Interstitial lung disease (ILD) is a common, devastating pulmonary complication. An increased number of reports suggesting that biological disease modifying antirheumatic drugs (DMARDs) induced or exacerbated ILDs in rheumatoid arthritis (RA) patients has garnered increased attention.
Areas covered: This article discusses ILDs induced by or exacerbated during biological therapy in RA patients. The article summarizes the efficacy and safety of a variety of licensed and off-label biologics clinically used for rheumatic diseases, focusing on the onset or exacerbation of RA-associated ILDs (RA-ILDs) in RA patients treated with biologics targeting tumor necrosis factor, CD20, interleukin 1 (IL-1) and IL-6 receptors. Additionally, the pathogenesis of RA-ILDs is discussed.
Expert opinion: To some extent, the possibility of biologic-induced RA-ILDs increases the difficulty in choosing an optimal regimen for RA treatment with biological agents, as the relationship between biological therapy safety and the induction or exacerbation of RA-ILDs has not been established. A framework to assess baseline disease severity, particularly standardizing the evaluation of the pulmonary condition stage in RA patients and monitoring the outcome during the biological therapy treatment, is highly needed and may substantially help guide treatment decisions and predict the treatment benefits.
Details
- Title: Subtitle
- Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies
- Creators
- Juan Chen - Department of Pulmonary and Critical Care Medicine, General Hospital of Ningxia Medical UniversityShuhong Chi - Department of Rheumatology, General Hospital of Ningxia Medical UniversityFeng Li - Center of Laboratory Medicine, General Hospital of Ningxia Medical UniversityJiali Yang - Human Stem Cell Institute, General Hospital of Ningxia Medical UniversityWilliam C Cho - Department of Clinical Oncology, Queen Elizabeth HospitalXiaoming Liu - Human Stem Cell Institute, General Hospital of Ningxia Medical University
- Resource Type
- Journal article
- Publication Details
- Expert opinion on biological therapy, Vol.17(3), pp.265-283
- Publisher
- Taylor & Francis
- DOI
- 10.1080/14712598.2017.1287169
- PMID
- 28117616
- ISSN
- 1471-2598
- eISSN
- 1744-7682
- Grant note
- 31472191; 81360004 / National Natural Science Foundation of China (10.13039/501100001809)
- Language
- English
- Date published
- 03/04/2017
- Academic Unit
- Anatomy and Cell Biology
- Record Identifier
- 9984025481402771
Metrics
25 Record Views